Scholars Central

Conference abstractPublished 22 May 2017

Low-dose oral acetylcysteine in the attenuation of cisplatin-induced nephrotoxicity: A randomized double-blind placebo-controlled pilot trial in patients with head and neck cancer

Authors: Marilia B Visacri

University of Campinas, Brazil

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Statement of the Problem: Cisplatin chemotherapy induces oxidative stress and therefore has consequent toxicities. The main dose-limiting side effect of cisplatin is nephrotoxicity. The protective antioxidant role of acetylcysteine (NAC) on nephrotoxicity due to cisplatin has been reported in experimental models; however, its efficacy in patients has not been elucidated. The aim of this study was to evaluate the possible protective effect of low-dose oral NAC on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Methodology & Theoretical Orientation: This is a randomized double-blind placebo-controlled pilot trial conducted with 57 patients undergoing treatment with at least one of the three cycles of high-dose cisplatin chemotherapy, concomitant to radiotherapy. Patients were randomly assigned and were given: (1) NAC syrup, 600 mg orally once a day at night for 7 consecutive days (two days before the chemotherapy, on the day of chemotherapy and 4 days after chemotherapy), n=28; or (2) Placebo, administered similarly to NAC, n=29. Plasma levels of creatinine were monitored to assess nephrotoxicity. Creatinine clearance was estimated using the Cockroft-Gault formula. Severity was classified by Common Toxicity Criteria for Adverse Events (version 4, grade 0 to 4). Findings: Patients from both groups had similar demographics and clinical characteristics (p>0.05). Throughout the treatment, elevated creatinine was observed in 55.2% of patients in placebo group (grade 1+2: 34.5%; grade 3: 20.7%) and 64.3% in NAC group (grade 1+2: 46.4%; grade 3: 17.9%) [Chi-square test, p=0.6517]. Moreover, reduced creatinine clearance was observed in 96.6% of patients in placebo group (grade 1+2: 75.9%; grade 3+4: 20.7%) and 96.4% in NAC group (grade 1+2: 82.1%; grade 3+4: 14.3%) [Fisher's exact test, p=0.8620]. Conclusion & Significance: Low-dose oral NAC did not attenuate cisplatin-induced nephrotoxicity. Further studies should be conducted to test other oral doses of NAC.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectDentistry & Oral Health
  • SubjectNephrology & Urology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Marilia B Visacri”